Phil Engel
Operations manager over distribution and manufacturing. Outside of work I read the research on health and longevity, lifting, MMA, the markets, and AI — and I write up what I find.
Supplement & Peptide Guides
All 36 →Evidence-honest summaries of health and medical topics — what the trials show and what practising physicians report, including where they disagree. Every claim is sourced.
GLP-1 Receptor Agonists: The 3-Receptor Ladder (Single, Dual, Triple)
The pharmacology behind Ozempic, Zepbound and retatrutide, in plain language. GLP-1 is a natural gut hormone and an agonist is a drug that mimics it; newer drugs…
KPV Peptide: What the Research Actually Shows — Mouse Gut Data, Almost No Human Trials
KPV is the three-amino-acid tail of α-MSH. Mouse colitis papers (PepT1, NF-κB) are real and mechanistic. Native KPV has no placebo-controlled human RCT we could…
Nandrolone (Deca-Durabolin): The 1962 FDA-Approved Anemia Drug Bodybuilders Never Gave Back
Nandrolone (Deca) is a 1962 FDA-approved anabolic steroid — never withdrawn for safety, still Schedule III, still made by zero US manufacturers — with a genuinely…
MOTS-c: The "Exercise in a Vial" Peptide — 247 Papers, Zero Completed Human Trials, One That Just Started
MOTS-c is a mitochondrial-derived peptide marketed as 'exercise in a vial' — 247 papers of strong preclinical metabolic and exercise-mimetic data, but zero completed…
The Mitochondrial Triple Stack: MOTS-c + SS-31 + NAD+ — What's Actually Tested vs. What's Taught
The MOTS-c + SS-31 + NAD+ 'mitochondrial stack' — separating the real trial evidence behind each component from the marketing that bundles them into one protocol.
SS-31 (Elamipretide): The Peptide That Failed Four Trials and Got Approved for $800,000 a Year
SS-31 (elamipretide/Bendavia) is a cardiolipin-binding mitochondrial peptide with strong preclinical mechanism data — but four separate placebo-controlled human RCTs…
Recently added videos
newest across every category
